Oncobiologics, a privately held biopharmaceutical company, and Laboratorios Liomont, a Mexico City-based pharmaceutical company, have partnered for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market. The agreement includes exclusive commercialization in Mexico by Liomont of two biosimilars developed by Oncobiologics.
Liomont will provide Oncobiologics with upfront licensing and development milestone payments, as well as royalties once the medicines are commercialized. Oncobiologics will oversee global clinical trials and will provide commercial supply manufacturing for launch in the Mexican market.
Financial terms have not been disclosed.